FTXH vs. CNCR

Last updated Jun 5, 2026

FTXH (First Trust Nasdaq Pharmaceuticals ETF) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds - FTXH tracks the Nasdaq U.S. Smart Pharmaceuticals Index while CNCR tracks the Loncar Cancer Immunotherapy Index. Both are passively managed. FTXH charges 0.60%/yr vs 0.79%/yr for CNCR.

Performance

FTXH vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in First Trust Nasdaq Pharmaceuticals ETF (FTXH) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

FTXH

• 1D: 2.50%
• 1M: 3.66%
• YTD: 7.62%
• 6M: 9.20%
• 1Y: 39.54%
• 3Y*: 12.33%
• 5Y*: 8.33%
• 10Y*: —

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

FTXH vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
FTXH First Trust Nasdaq Pharmaceuticals ETF	0.15%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

FTXH vs. CNCR - Sectors Allocation Comparison

Sectors	FTXH	CNCR
Healthcare	100.0%	96.6%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Financial Services	-	3.3%
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

FTXH vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

FTXH

FTXH Risk / Return Rank: 77
FTXH Sharpe Ratio Rank: 72
FTXH Sortino Ratio Rank: 77
FTXH Omega Ratio Rank: 67
FTXH Calmar Ratio Rank: 89
FTXH Martin Ratio Rank: 80

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

FTXH vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for First Trust Nasdaq Pharmaceuticals ETF (FTXH) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	FTXH	CNCR	Difference
Sharpe ratio: Return per unit of total volatility	2.32	—	—
Sortino ratio: Return per unit of downside risk	3.40	—	—
Omega ratio: Gain probability vs. loss probability	1.39	—	—
Calmar ratio: Return relative to maximum drawdown	5.32	—	—
Martin ratio: Return relative to average drawdown	15.35	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	FTXH	CNCR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.32	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.51	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.39	—	—

Drawdowns

FTXH vs. CNCR - Drawdown Comparison

The maximum FTXH drawdown since its inception was -32.11%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for FTXH and CNCR.

Drawdown Indicators

	FTXH	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-32.11%	0.00%	-32.11%
Max Drawdown (1Y) Largest decline over 1 year	-7.47%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-19.51%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-19.51%	—	—
Current Drawdown Current decline from peak	-0.45%	0.00%	-0.45%
Average Drawdown Average peak-to-trough decline	-5.84%	0.00%	-5.84%
Ulcer Index Depth and duration of drawdowns from previous peaks	2.58%	—	—

Volatility

Volatility by Period

	FTXH	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	5.38%	—	—
Volatility (6M) Calculated over the trailing 6-month period	11.96%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	17.14%	0.00%	+17.14%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	16.34%	0.00%	+16.34%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	18.43%	0.00%	+18.43%

FTXH vs. CNCR - Expense Ratio Comparison

FTXH has a 0.60% expense ratio, which is lower than CNCR's 0.79% expense ratio.

Dividends

FTXH vs. CNCR - Dividend Comparison

FTXH's dividend yield for the trailing twelve months is around 1.19%, while CNCR has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
FTXH First Trust Nasdaq Pharmaceuticals ETF	1.19%	1.41%	1.66%	1.55%	1.11%	1.03%	0.82%	0.67%	0.91%	2.18%	0.19%

Frequently Asked Questions

Which ETF is better, FTXH or CNCR?

On fees, FTXH is cheaper at 0.60% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, FTXH or CNCR?

FTXH is cheaper with a 0.60% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, FTXH or CNCR?

FTXH has the higher dividend yield at 1.19%, compared with 0.00% for CNCR.

What is the main difference between FTXH and CNCR?

FTXH tracks Nasdaq U.S. Smart Pharmaceuticals Index, while CNCR tracks Loncar Cancer Immunotherapy Index. They also come from different issuers: First Trust and Exchange Traded Concepts. Their fees differ too: 0.60% for FTXH and 0.79% for CNCR.